| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sammy Saab | Q88094221 |
| P2093 | author name string | Michael Chang | |
| Hubert Sung | |||
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C | Q28348712 | ||
| Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin | Q28360270 | ||
| Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage | Q28374338 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection | Q33343858 | ||
| Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. | Q33377599 | ||
| Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes | Q33379835 | ||
| Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag | Q33387808 | ||
| Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa | Q33489322 | ||
| Immune thrombocytopenia and alpha-interferon therapy | Q33498289 | ||
| Hepatitis C and interferon induced thyroiditis | Q33716540 | ||
| Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response | Q33956478 | ||
| Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study | Q34725432 | ||
| Side effects of therapy of hepatitis C and their management | Q34984142 | ||
| Side effects of therapy for chronic hepatitis C. | Q35133495 | ||
| The management of side-effects during therapy for hepatitis C. | Q35936934 | ||
| Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy | Q36775650 | ||
| Ribavirin: current role in the optimal clinical management of chronic hepatitis C. | Q37353333 | ||
| Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin | Q37364301 | ||
| Interferon alpha and neuromuscular disorders | Q37378184 | ||
| Chronic viral hepatitis as a public health issue in the world | Q37383749 | ||
| Quality of life considerations for patients with chronic hepatitis C. | Q37578733 | ||
| Managing depression during hepatitis C treatment | Q37596596 | ||
| Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review | Q37621850 | ||
| Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. | Q38876960 | ||
| ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. | Q39920642 | ||
| Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis | Q41743574 | ||
| Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke | Q42413495 | ||
| Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. | Q42987479 | ||
| Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C. | Q42992498 | ||
| Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate | Q42999332 | ||
| The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. | Q43011629 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. | Q43425647 | ||
| A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. | Q44194141 | ||
| Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. | Q44911029 | ||
| Factors contributing to ribavirin-induced anemia | Q45105371 | ||
| Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. | Q45234522 | ||
| Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection | Q45741084 | ||
| Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. | Q46104405 | ||
| Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial | Q46790729 | ||
| Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. | Q50577784 | ||
| Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. | Q50583960 | ||
| Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. | Q50585335 | ||
| Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. | Q54018637 | ||
| Retinal complications during interferon therapy for chronic hepatitis C | Q71015917 | ||
| Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy | Q71401679 | ||
| The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C | Q72279816 | ||
| Localized interferon alfa-2b-induced alopecia | Q72999793 | ||
| Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients | Q73351810 | ||
| Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C | Q81550180 | ||
| P433 | issue | 1 | |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 33-40 | |
| P577 | publication date | 2010-12-24 | |
| P1433 | published in | Current hepatitis reports | Q26853829 |
| P1476 | title | Management of Hepatitis C Antiviral Therapy Adverse Effects | |
| P478 | volume | 10 |
| Q34241691 | "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis |
| Q38051248 | A new era in the treatment of chronic hepatitis C infection |
| Q27023355 | A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection |
| Q87924400 | Chronic Hepatitis C Infection in Children |
| Q26781770 | Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies |
| Q92480921 | Comparing drug safety of hepatitis C therapies using post-market data |
| Q36966151 | Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India |
| Q36059685 | Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C |
| Q36175105 | Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report. |
| Q38282842 | New treatments for chronic hepatitis C: an overview for paediatricians |
| Q40878993 | Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection |
| Q100384122 | Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review |
| Q35835981 | Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey |
| Q33621649 | The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. |
Search more.